Research Articles

Research Article

Sex Disparities in ICH: Presentation, Care, and Outcomes in the TICH-2 Trial.

Women With ICH Show Similar Adjusted 90-Day Outcomes to Men Despite Greater Baseline Severity — Despite presenting older, with larger haematomas, worse pre-stroke function, and higher rates of early resuscitation limitations, women with intracerebral haemorrhage had functionally equivalent outcomes to men at 90 days after adjustment for prognostic factors, with no meaningful difference in the odds of poor outcome (aOR 1.04, 95% CI 0.88–1.22).

Oct 1, 2026 · Cerebrovasc Dis · Neurology

79

Research Article

Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).

REDEFINE 3 Trial Enrolls 7,076 Adults to Test CagriSema on Cardiovascular Outcomes — The REDEFINE 3 trial has completed enrollment of 7,076 adults with established cardiovascular disease and excess adiposity, randomizing participants to the fixed-dose combination CagriSema or placebo in the first large-scale cardiovascular outcomes trial for this dual receptor agonist.

Oct 6, 2026 · Am Heart J · Neurology

79

Research Article

Inhaled Heparin to Shorten Antibiotic Duration in Ventilator-Associated Pneumonia: A Randomized Double-Blind Controlled Trial.

Nebulized Heparin Cuts Antibiotic Duration by Three Days in Ventilator-Associated Pneumonia — In a randomized double-blind trial, mechanically ventilated adults with ventilator-associated pneumonia (VAP) who received adjunctive nebulized heparin required approximately 3.2 fewer days of antibiotics than those receiving placebo (mean difference −3.2 days; 95% CI: −4.8 to −1.6; p < 0.001), with the effect holding after statistical adjustment for a baseline severity imbalance (adjusted mean difference −2.9 days; 95% CI: −4.5 to −1.3; p = 0.001).

Oct 5, 2026 · Health Sci Rep · Infectious Diseases

80

Randomized Controlled Trial

A Composite Ovine Forestomach Matrix and Hyaluronic Acid CAMP for the Treatment of Full Thickness Wounds of the Foot in People With Diabetes: A Randomized Controlled Trial.

Novel OFM-HA Composite Dressing Nearly Doubles 12-Week Healing Rates in Diabetic Foot Ulcers — In a randomized controlled trial of 143 patients, adding a composite ovine forestomach matrix and hyaluronic acid product (OFM-HA) to standard of care resulted in wound closure in 46% of patients by 12 weeks, compared with 24% receiving standard of care alone (p = 0.008).

2026 · Int Wound J · Metabolism

80

Meta-Analysis

Cellular, Acellular, and Matrix-Like Placental Products for Diabetic Foot Ulcers: A 12-Week Randomised-Trial Meta-Analysis.

Placental-Derived CAMPs Show 70% Higher 12-Week Closure Rate for Diabetic Foot Ulcers — Adults with diabetic foot ulcers treated with placental-derived cellular, acellular, and matrix-like products (CAMPs) as an adjunct to standard care achieved complete wound closure at 12 weeks nearly 70% more often than those receiving standard care alone (59.0% vs. 35.8%; RR 1.70, 95% CI 1.31–2.20).

2026 · Int Wound J · Metabolism

80

Meta-Analysis

Cardiovascular safety in middle-aged and older men under testosterone replacement therapy: a systematic review and meta-analysis.

TRT Improves Lipid and Vascular Markers but Raises Arrhythmia Concern in Older Men — A meta-analysis of 31 randomised controlled trials found that testosterone replacement therapy (TRT) significantly reduced LDL cholesterol by approximately 6.6 mg/dL (WMD: −6.64 mg/dL, 95% CI: −8.65 to −4.63) and improved ischemic and vascular markers, while also revealing an approximately 58% higher odds of arrhythmia compared with placebo (OR: 1.58, 95% CI: 1.21–2.05).

Oct 6, 2026 · Endocrine · Neurology

80

Randomized Controlled Trial

N-acetylcysteine mouthwash for prevention of oral mucositis in hematopoietic cell transplant recipients: a double-blind randomized controlled trial.

NAC Mouthwash Significantly Reduces Severe Oral Mucositis in HCT Recipients — In a double-blind randomized controlled trial of 106 adults undergoing hematopoietic cell transplantation, prophylactic N-acetylcysteine (NAC) mouthwash reduced severe oral mucositis nearly five-fold compared with placebo — 5.6% versus 25.0% of patients affected (P = 0.006) — though overall mucositis incidence was not significantly different between groups.

Oct 4, 2026 · Support Care Cancer · Oncology

81

Clinical Trial

Giredestrant plus Everolimus in Advanced Breast Cancer.

Giredestrant Plus Everolimus Cuts Disease Progression Risk by 44% in Advanced ER-Positive Breast Cancer — In a phase 3 randomised trial of 373 patients with ER-positive, HER2-negative advanced breast cancer who had progressed on a CDK4/6 inhibitor, adding giredestrant to everolimus nearly halved the risk of disease progression or death compared with standard endocrine therapy plus everolimus, with a median progression-free survival of 8.8 months versus 5.5 months overall (HR 0.56, 95% CI 0.44–0.71, P<0.001).

Oct 1, 2026 · N Engl J Med · Oncology

82

Clinical Trial

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

AMH Level, Not Menopausal Status, Predicts Adjuvant Chemotherapy Benefit in HR-Positive Breast Cancer — Among premenopausal women under 55 with hormone receptor-positive, HER2-negative breast cancer, those with normal ovarian reserve (AMH ≥10 pg/ml) gained substantial benefit from adding chemotherapy to endocrine therapy — roughly 54% lower risk of invasive disease progression (HR 0.46, 95% CI 0.33–0.65) — while those with low ovarian reserve (AMH <10 pg/ml) showed no meaningful benefit and a non-significant trend toward harm (HR 1.27, 95% CI 0.81–1.99).

Jul 24, 2026 · Ann Oncol · Oncology

83

Clinical Trial

Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.

Felzartamab Added to Standard Doublet Nearly Doubles Progression-Free Survival in Relapsed Myeloma — In a randomised phase 3 trial of Chinese patients with relapsed or refractory multiple myeloma, adding felzartamab to lenalidomide-dexamethasone extended median progression-free survival from 10.4 months to 18.9 months — approximately 38% lower risk of progression or death (HR 0.62, 95% CI 0.45–0.86; p=0.0035).

2026 · Lancet Haematol · Oncology

85